Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-10-11
2011-10-11
Wen, Sharon (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100
Reexamination Certificate
active
08034345
ABSTRACT:
The present invention relates to uses of PCI, which inhibits HGFa activity, and to uses of anti-PCI antibodies, which neutralize HGFa inhibition; and to agents for regulating and controlling tissue regeneration and/or repair, with PCI as an active ingredient; and to agents for enhancing tissue regeneration and/or repair, with anti-PCI antibodies as active ingredients (particularly, anti-PCI antibodies with the action of neutralizing PCI (anti-PCI neutralizing antibodies)).
REFERENCES:
patent: 6593291 (2003-07-01), Green et al.
patent: 2006/0167230 (2006-07-01), Koga et al.
patent: 2009/0170760 (2009-07-01), Suzuki
patent: 63-233927 (1988-09-01), None
patent: 2002-000273 (2002-01-01), None
USPTO Restriction Requirement in U.S. Appl. No. 11/911,754, dated Dec. 2, 2009, 5 pages.
Fish & Richardson P.C., Response to Restriction Requirement dated Dec. 2, 2009 in U.S. Appl. No. 11/911,754, filed Dec. 23, 2009, 1 page.
USPTO Non-Final Office Action in U.S. Appl. No. 11/911,754, dated Feb. 19, 2010, 12 pages.
Asanuma et al., “Protein C inhibitor inhibits breast cancer cell growth, metastasis and angiogenesis independently of its protease inhibitory activity,” Int. J. Cancer, 121:955-965 (2007).
Kuhn et al., “Elicidating the structural chemistry of glycosaminoglycan recognition by protein C inhibitor”, Proc. Natl. Acad. Sci. USA 87:8506-8510, 1990.
Shirk et al., “Role of the H helix in heparin binding to protein C inhibitor”, The Journal of Biological Chemistry 269(46):28890-28895, 1994.
Stief et al., “Evidence for identity of PCI and plasminogen activator inhibitor 3”, Biol. Chem. Hoppe-Seyler 368:1427-1433, 1987.
Stump et al., “Purification and characterization of a novel imhibitor of urokinase from human urine”, The Journal of Biological Chemistry 261(27):12750-12766, 1986.
Suzuki et al., “Protein C inhibitor”, The Journal of Biological Chemistry 258(1):163-168, 1983.
Suzuki et al., “Characterization of a cDNA for human protein C inhibitor”, The Journal of Biological Chemistry 262(2):611-616, 1987.
Fair and Marlar, “Biosynthesis and Secretion of Factor VII, Protein C, Protein S, and the Protein C Inhibitor From a Human Hepatoma Cell Line,”Blood, 67(1):64-70 (1986).
Hamada et al., “Protein C inhibitor regulates hepatocyte growth factor activator-mediated liver regeneration in mice,”Gut, 57:365-373 (2008).
European Search Report for App. Ser. No. EP 05 79 3705, dated Feb. 12, 2009, 5 pages.
Japanese Patent Office, International Search Report for App. Ser. No. PCT/JP2006/308095, mailed Jul. 25, 2006, 5 pages.
International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/308095, dated Oct. 23, 2007, 6 pages.
Akita et al., “Protein C Inhibitor (PCI) inhibits invasion and matastasis of melanoma cells”, Japanese Journal of Thrombosis and Hemostasis, 14(5):443, 2003.
Elisen et al., “Protein C Inhibitor Acts As A Procoagulant by Inhibiting the Thrombomodulin-Induced Activation of Protein C in Human Plasma”, Blood, 91:1542-1547, 1998.
Francis Jr. et al., “Behaviour of Protein C Inhibitor in Intravascular Coagulation and Liver Disease”, Thromb Haemostas, 52:71-74, 1984.
Hayashi et al., “Characterization of a Novel Human Protein C Inhibitor (PCI) Gene Transgenic Mouse Useful for Studying the Role of PCI in Physiological and Pathological Conditions”, Journal of Thrombosis and Haemostas, 2:949-961, 2004.
Jackson et al., “Assessment of the interaction between urokinase and reactive site mutants of protein C inhibitor”, Journal of Protein Chemistry 16(8):819-828, 1997.
Joyce et al., “Gene Expression Profile of Antithrombotic Protein C Defines New Mechanisms Modulating Inflammation and Apoptosis”, The Journal of Biological Chemistry, 276:11199-11203, 2001.
Kaido et al., “Expressions of Molecules Associated with Hepatocyte Growth Factor Activation After Hepatectomy in Liver Cirrhosis”, Hepato-gastroenterology, 51:547-551, 2004.
Marlar et al., “Deficiency of Protein C Inhibitor in Combined factor V/VIII Deficiency Disease”, J. Clin. Invest., 66:1186-1189, 1980.
Suzuki et al., “Mechanism of Inhibition of Activated Protein C”, J. Biochem. 95:187-195, 1984.
Suzuki et al., “Protein C Inhibitor Plays a Role as a Potent Regulator of Activated Hepatocyte Growth Factor Activator”, Journal of Thrombosis and Haemostasis, 3(Suppl. 1):Abstract No. OR001, Abstracts from XXth ISTH Congress, Aug. 2005.
Suzuki, “Protein C Inhibitor (PAI-3): Structure and Multi-Function”, Fibrinolysis and Proteolysis, 14:133-145, 2000.
Taylor Jr. et al., “DEGR-Factor Xa Blocks Disseminated Intravascular Coagulation Initiated byEscherichia coliWithout Preventing Shock or Organ Damage”, Blood, 78:364-368, 1991.
Taylor Jr. et al., “Protein C Prevents the Coagulopathic and Lethal Effects ofEscherichia coliInfusion in the Baboon”, J. Clin. Invest., 79:918-925, 1987.
Wakita et al., “Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreased in renal cell carcinoma”, Intl. J. Cancer 108(10):516-523, 2004.
Xue et al., “Hepatocyte Growth Factor Gene Therapy Accelerates Regeneration in Cirrhotic Mouse Livers After Hepatectomy”, Gut, 52:694-700, 2003.
Saito Hiroyuki
Suzuki Koji
Chugai Seiyaku Kabushiki Kaisha
Fish & Richardson P.C.
Mie University
Wen Sharon
LandOfFree
Anti-PCI antibody for regulating liver regeneration/repair does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-PCI antibody for regulating liver regeneration/repair, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-PCI antibody for regulating liver regeneration/repair will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4277170